1.646.889.1200|info@lifescipublicrelations.com

Why Gilead could pay more than $2 billion in deal with this small S.F. biotech

//Why Gilead could pay more than $2 billion in deal with this small S.F. biotech

Why Gilead could pay more than $2 billion in deal with this small S.F. biotech

Founded by three professors from UC Berkeley and UCSF, Nurix’s protein-degradation approach to cancer, and potentially other diseases, could stop cancer in its tracks.

By | 2019-06-24T11:59:33-04:00 June 19th, 2019|News|Comments Off on Why Gilead could pay more than $2 billion in deal with this small S.F. biotech

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.